Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.91
+0.11 (2.29%)
Bozor ochiq: Aug 12, 2026, 1:56 PM EDT
4.71
-0.09 (-1.88%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Immuneering Corporation, kechki bosqichdagi onkologiya kompaniyasi, Qo'shma Shtatlarda keng ko'lamdagi rak bemorlari uchun dori vositalarini ishlab chiqadi. Kompaniya IMM-1-104 (atebimetinib) ni ishlab chiqadi, bu RAS yoki RAF mutatsiyalari bilan bog'liq oshqozon osti bezi va mayda hujayrali o'pka rakini o'z ichiga olgan bemorlarni davolash uchun 3-bosqichli klinik sinovda bo'lgan qo'sh MEK inhibitori; IMM-6-415 (envometinib), bu qattiq o'smalari bo'lgan bemorlarni davolash uchun 1/2a-bosqichli klinik sinovda; va bir nechta chuqur tsiklik inhibitorlarni kashf qilish dasturlari. Kompaniya unresectable yoki metastatik RAS-mutantli mayda hujayrali o'pka rakiga ega bemorlarda Libtayo bilan birgalikda atebimetinibni baholash uchun Regeneron Pharmaceuticals bilan klinik ta'minot shartnomalariga ega; va Eli Lilly and Company bilan birgalikda olomorasib bilan birgalikda KRAS G12C-mutantli mayda hujayrali o'pka rakiga ega bemorlarda atebimetinibni baholash uchun. Immuneering Corporation 2008 yilda ro'yxatdan o'tgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Mr. Andrew W. Gengos | CFO & Treasurer |
| Mr. David Caouette | Vice President of Corporate Communications |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus |
| Ms. Jyoti Joshi | Director of Quality Systems & Compliance |
| Ms. Leah R. Neufeld | Chief People Officer |
| Ms. Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer |
| Ms. Paula George CPA | Senior Director of Accounting & Operations and Assistant Corporate Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-05 | 10-Q | imrx-20260630.htm |
| 2026-06-15 | 8-K | imrx-20260611.htm |
| 2026-06-11 | 8-K | imrx-20260611.htm |
| 2026-06-01 | 8-K | imrx-20260601.htm |
| 2026-05-15 | 10-Q | imrx-20260331.htm |
| 2026-04-20 | DEFA14A | imrx-2026additionalproxyma.htm |
| 2026-04-20 | DEF 14A | imrx-20260420.htm |
| 2026-03-06 | 8-K | imrx-20260306.htm |
| 2026-03-06 | 10-K | imrx-20251231.htm |
| 2026-01-07 | 8-K | imrx-20260107.htm |